In DN and metabolic disease, genotype-dependent responses linked to ACE I/D, eNOS, and SOD2 polymorphisms complicate drug selection, while non-vasodilating BBs can exacerbate insulin resistance and dyslipidemia. Here, ACE is linked to metabolic syndrome.